Clinical trials: Arthritis, Rheumatoid
Type2diabetes, Rheumatoid Arthritis
Understanding Ayurveda Disease Conditions and Treatment Responses
The goal of this observational study is to assess Prakriti \& Vikriti in patients visiting OPD of IIISM department, SRM hospital.
- Conditions
- Type2diabetes, Rheumatoid Arthritis, Osteo Arthritis Knee, Skin Diseases
- Trial name
- NCT06167226
- Testing
- Personalized Ayurveda treatment protocol
- Where
- India
- Volunteers
- 497 people
- Sponsor
- Ayurai Private Limited
Anemia, Rheumatoid Arthritis
Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety profile of epoetin alfa in patients with anemia of chronic disease due to rheumatoid arthritis
- Trial name
- NCT00123149
- Testing
- Epoetin alfa
- Sponsor
- Ortho Biotech Products, L.P.
Rheumatoid Arthritis
A Study of Iguratimod in Patients With Active Rheumatoid Arthritis
This study is intended to evaluate the safety and efficacy of Iguratimod in patients with active Rheumatoid Arthritis.
- Trial name
- NCT01554917
- Testing
- Iguratimod
- Where
- China
- Volunteers
- 1,759 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Arthritis, Rheumatoid
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
This study will be conducted to observe the disease activity change of Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARD) plus anti-tumour necrosis factor (anti-TNF) from baseline to 6 months compared with cDMARDs, as…
- Trial name
- HUMAN (NCT03264703)
- Where
- 15 sites in South Korea
- Volunteers
- 212 people
- Sponsor
- Eisai Korea Inc.
Rheumatoid Arthritis
Phase IIIB Subcutaneous Missed Dose Study
The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.
- Trial name
- NCT00533897
- Testing
- Abatacept
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Moderate-to-severe Rheumatoid Arthritis
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
The purpose of this study is to evaluate the clinical effectiveness and safety of adalimumab as used in routine clinical practice in adult participants with moderate to severe rheumatoid arthritis (RA) in Canada.
- Trial name
- REACH (NCT01117480)
- Volunteers
- 1,013 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
- Trial name
- NCT05363891
- Testing
- Natrunix
- Where
- 26 sites in United States
- Volunteers
- 243 people
- Sponsor
- XBiotech, Inc.
Rheumatoid Arthritis (RA)
A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
- Trial name
- NCT07234773
- Testing
- KT501
- Where
- Australia
- Volunteers
- 24 people
- Sponsor
- Kali Therapeutics, Inc.
Rheumatoid Arthritis
Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
The objective of this study is to investigate if low doses of prednisone MR formulation, given at night and, with active drug release at 2 am, are more effective in controlling joint stiffness, and other disease symptoms of…
- Trial name
- NCT00146640
- Testing
- MR Prednisone, IR Prednisone
- Where
- 24 sites in Germany, Poland
- Volunteers
- 288 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01615419
- Where
- 9 sites in Greece
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA.
- Trial name
- NCT01146652
- Testing
- SAR153191 (REGN88)
- Where
- 335 sites in United States, Argentina and 38 more
- Volunteers
- 2,023 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis
Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with…
- Trial name
- NCT00207714
- Testing
- Golimumab, MTX, Infliximab
- Volunteers
- 172 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
An observational study to determine the risk of cancer associated with the use of abatacept and other biologic agents among rheumatoid arthritis patients
- Trial name
- NCT03670667
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 1,132 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
The main objective of the study is to evaluate the safety and tolerability of six escalating doses of SCIO-469 in RA patients. SCIO-469 belongs to a new class of treatments that inhibit p38 kinase, a stimulatory modulator of…
- Trial name
- NCT00043732
- Testing
- SCIO-469
- Volunteers
- 120 people
- Sponsor
- Scios, Inc.
Rheumatoid Arthritis
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
- Trial name
- NCT02047604
- Testing
- SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bausch Health Americas, Inc.
Healthy, Systemic Lupus Erythematosus
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
- Conditions
- Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT07276958
- Testing
- LY4298445
- Where
- 10 sites in Australia, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Osteoarthritis
PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis
- Trial name
- PRESENT (NCT00576706)
- Testing
- Rebamipide, Misoprostol
- Where
- 10 sites in South Korea
- Volunteers
- 396 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups of HL237 tablets and the control group.
- Trial name
- NCT04638426
- Testing
- HL237 tablet
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Hanlim Pharm. Co., Ltd.